Changes in serum fibrogenesis markers during interferon therapy for chronic hepatitis type C

Hepatology

Volumn 24, Issue 1, 1996, Pages 27-31

  Ishibashi, Kazunobu ^a   Kashiwagi, Toru ^a   Ito, Akihiko ^a   Tanaka, Yoshio ^a   Nagasawa, Masafumi ^a   Toyama, Takashi ^a   Ozaki, Shiniti ^a   Naito, Masafumi ^a   Azuma, Masayoshi ^a  

^a OSAKA KOSEI NENKIN HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON;

ADULT; AGED; ARTICLE; DRUG EFFECT; FEMALE; FIBROGENESIS; HEPATITIS C; HISTOPATHOLOGY; HUMAN; IMMUNOTHERAPY; INTRAMUSCULAR DRUG ADMINISTRATION; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0029979128     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.1996.v24.pm0008707274     Document Type: Article

References (25)

1. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, Carey W, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 1989;321:1501-1506.
2. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989;321:1506-1510.
3. Hagiwara H, Hayashi N, Mita E, Takehara T, Kasahara A, Fusamoto H, Kamada T, et al. Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology 1993;104:877-883.
4. Risteli J, Risteli L. Analysing connective tissue metabolites in human serum. Biochemical, physiological and methodological aspects. J Hepatol 1995;22(suppl 2):77-81.
5. Biagini G, Ballardini G. Liver fibrosis and extracellular matrix. J Hepatol 1989;8:115-124.
6. Niemela O, Risteli L, Sotaniemi EA, Risteli J. Type IV collagen and laminin-related antigens in human serum in alcoholic liver disease. Eur J Clin Invest 1985;15:132-137.
7. Engstrom-Laurent A, Loof L, Nyberg A, Schroder T. Increased serum levels of hyaluronate in liver disease. HEPATOLOGY 1985;5:638-642.
8. Gibson PR, Fraser JRE, Brown TJ, Finch CF, Jones PA, Colman JC, Dudley FJ. Hemodynamic and liver function predictors of serum hyaluronan in alcoholic liver disease. HEPATOLOGY 1992;15:1054-1059.
9. Capra F, Casaril M, Gabrielli GB, Tognella P, Rizzi A, Dolci L, Colombari R, et al. α-Interferon in the treatment of chronic viral hepatitis: effects on fibrogenesis serum marker. J Hepatol 1993;18:112-118.
10. Teran JC, Mullen KD, Hoofnagle JH, McCullough AJ. Decrease in serum levels of markers of hepatic connective tissue turnover during and after treatment of chronic hepatitis B with interferon-α. HEPATOLOGY 1994;19: 849-856.
11. Groote J, Desmet VJ, Gedigh P, Korb G, Popper H, Poulsen H, Scheuer PJ, et al. A classification of chronic hepatitis. Lancet 1968;ii:626-628.
12. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kieran TW, et al. Formation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. HEPATOLOGY 1981;1:431-435.
13. Chichibu K, Matumura T, Shichijyo S, Yokoyama M. Assay of human hyaluronic acid in clinical application. Clin Chim Acta 1989;181:317-324.
14. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofhagle JH, Melpolder JJ, Alter H. Long-term clinical and histopathological follow-up of chronic post-transfusion hepatitis. HEPATOLOGY 1991;14:969-974.
15. Czaja MJ, Weiner FR, Eghbali M, Giambrone MA, Eghbali M, Zern MA. Differential effects of γ-interferon on collagen and fibronectin gene expression. J Biol Chem 1987;262:13348-13351.
16. Granstein RD, Flotte TJ, Amento EP. Interferons and collagen production. J Invest Dermatol 1990;95:75S-80S.
17. Tsutsumi Y, Kakumu S, Yoshioka K, Arao M, Inoue M, Wakita T. Effects of various cytokines on collagen synthesis by normal rat hepatocytes in primary cultures and fibroblasts. Digestion 1989;44:191-199.
18. Czaja MJ, Weiner FR, Takahashi S, Giambrone MA, Meide PH, Schellekens H, Biempica L, et al. γ-interferon treatment inhibit collagen deposition in murine schistosomiasis. HEPATOLOGY 1989;10:795-800.
19. Jimenez SA, Freundlich B, Rosenbloom J. Selective inhibition of human diploid fibroblast collagen synthesis by interferons. J Clin Invest 1984;74: 1112-1116.
20. Castilla A, Prieto J, Fausto N. Transforming growth factor β1 and α in chronic liver disease. Effect of interferon alfa therapy. N Engl J Med 1991; 324:933-940.
21. Bentsen KD, Horn T, Risteli J, Risteli L, Engstrom-Laurent A, Horslev-Petersen K, Lorenzen I, et al. Serum aminoterminal type III procollagen peptide and the 7S domain of type IV collagen in patients with alcoholic abuse: relation to ultrastructural fibrosis in the acinar zone 3 and to serum hyaluronan. Liver 1987;7:339-346.
22. Timpl R, Glanville RW. The aminopropeptide of collagen. Clin Orthop 1981;158:224-242.
23. Guechot J, Loria A, Serfaty L, Giral P, Giboudeau J, Poupon R. Serum hyaluronan as a marker of liver fibrosis in chronic viral hepatitis C: effect of α-interferon therapy. J Hepatol 1995;22:22-26.
24. Plebani M, Burlina A. Biochemical markers of hepatic fibrosis. Clin Biochem 1991;24:219-239.
25. Ericksson S, Fraser JRE, Laurent TC, Pertoft H, Smedsrod B. Endothelial cells are a site of uptake and degradation of hyaluronic acid. A whole body autoradiographic study. Cell Tissue Res 1983;222:285-293.